Artios Pharma Announces Collaboration with Novartis to Create Next Generation DDR Cancer Therapies
• Novartis to leverage Artios’ discovery platform to identify DDR targets for use with Novartis’
proprietary radioligand therapies.
• Artios to receive US$20 million up-front payment in addition to near term research funding to
support the collaboration.
• Artios eligible to receive up to $1.3 billion in discovery, development, regulatory and sales-based
milestones in addition to royalty payments.
To read the press release, please click here